Intein-Assembled TALENs for Smaller Plasmids and Flexible Targeting

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing genome editing technologies using rare-cutting nucleases like TALENs face challenges in efficient delivery and flexibility due to large plasmid sizes and inflexible target specificity, limiting their application in precise gene editing.

Innovation Solution

The use of inteins to splice and ligate separate half TALENs and rare-cutting nucleases, allowing for smaller molecular complexes and increased expression frequency, with flexible target specificity through complementary inteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If TALENs are delivered as complete fusion proteins, then target specificity is maintained, but plasmid size becomes large and delivery efficiency decreases

Engineering Contradiction:
Improvetarget specificityVSAvoidplasmid size
Core Design Contradiction:
Measurement precisionVSWeight of stationary object

Solution Approach 1:

The TALEN system is divided into two separate components: a TALE protein and a nuclease domain. These are delivered as separate entities that can independently traverse the cell membrane and subsequently assemble through intein-mediated splicing to form the functional TALEN fusion protein, thereby reducing individual plasmid sizes while maintaining target specificity

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

An intein sequence is introduced as an intermediary element that facilitates the post-translational assembly of the TALE and nuclease components. The intein enables spontaneous splicing and ligation of the separate proteins after they enter the cell, allowing the formation of the complete TALEN fusion protein without requiring large plasmids to encode the entire fusion sequence

Inventive Principle:
Principle #24Intermediary (Mediator)

2Weight of stationary object

If TALEN components are delivered separately, then plasmid size is reduced and delivery efficiency improves, but assembly complexity increases

Engineering Contradiction:
Improveplasmid sizeVSAvoidassembly complexity
Core Design Contradiction:
Weight of stationary objectVSDevice complexity

Solution Approach 1:

The intein sequences are designed to enable self-splicing and self-ligation of the TALE and nuclease components after they enter the cell. This autonomous post-translational assembly process eliminates the need for complex external assembly procedures, reducing assembly complexity while allowing separate delivery of smaller plasmid components

Inventive Principle:
Principle #25Self-service

3Measurement precision

If traditional TALEN design is used, then target specificity is fixed, but flexibility in targeting different sequences is limited

Engineering Contradiction:
Improvetarget specificityVSAvoidtarget flexibility
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The TALE component is designed with modular repeats that can be dynamically reconfigured to recognize different DNA sequences. The intein-mediated assembly system allows for flexible combination of different TALE variants with the nuclease domain, enabling adaptation to various target sequences while maintaining precise binding through the modular TALE structure

Inventive Principle:
Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the efficiency and flexibility of gene editing by reducing plasmid size and improving target specificity, facilitating more effective transformation and editing of genetic material in cells.

Implementation Method 1

the first intein and the second intein are configured to self-splice when in contact and, in response, to form a first half transcription activator-like effector nuclease (TALEN) including the first TALE bound to the rare-cutting nuclease

Methodology Applied
Scientific EffectSelf-splicing: Enzyme

Data Source

PatentUS12590300B2Transcription activator-like effectors fused to inteins
Publication Date: 2026.03.31 CIBUS US LLC
  • US12590300B2 patent drawing
  • US12590300B2 patent drawing
  • US12590300B2 patent drawing

AI summary

Embodiments of the present disclosure are directed to a plurality of nucleotide sequences encoding a first intein fused to at least a portion of a first transcription activator-like effector (TALE), a second nucleotide sequence encoding the first intein fused to at least a portion of a second TALE, and a third nucleotide sequence encoding a second intein fused to at least a portion of a rare-cutting nuclease.